- Home
- Automated
- List of product information
- DICLECTIN DELAYED RELEASE TABLETS 10MG/10MG [SIN15301P]
DICLECTIN DELAYED RELEASE TABLETS 10MG/10MG [SIN15301P]
Active ingredients: DICLECTIN DELAYED RELEASE TABLETS 10MG/10MG
Last updated 26 October 2025
On this page
Product Info
DICLECTIN DELAYED RELEASE TABLETS 10MG/10MG
[SIN15301P]
Product information
Active Ingredient and Strength | DOXYLAMINE SUCCINATE - 10 MG |
Dosage Form | TABLET, DELAYED RELEASE |
Manufacturer and Country | DUCHESNAY INC. - CANADA |
Registration Number | SIN15301P |
Licence Holder | UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | R06AA59 |
1. INDICATIONS AND USAGE
DICLECTIN is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.
Limitations of Use
DICLECTIN has not been studied in women with hyperemesis gravidarum.
2. DOSAGE AND ADMINISTRATION
2.1 Dosage Information
Initially, take two DICLECTIN delayed-release tablets orally at bedtime (Day 1). If this dose adequately controls symptoms the next day, continue taking two tablets daily at bedtime. However, if symptoms persist into the afternoon of Day 2, take the usual dose of two tablets at bedtime that night then take three tablets starting on Day 3 (one tablet in the morning and two tablets at bedtime). If these three tablets adequately control symptoms on Day 4, continue taking three tablets daily. Otherwise take four tablets starting on Day 4 (one tablet in the morning, one tablet mid-afternoon and two tablets at bedtime).
The maximum recommended dose is four tablets (one in the morning, one in the mid-afternoon and two at bedtime) daily.
Take on an empty stomach with a glass of water [see Clinical Pharmacology (12.3) – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information]. Swallow tablets whole. Do not crush, chew, or split DICLECTIN tablets.
Take as a daily prescription and not on an as needed basis. Reassess the woman for continued need for DICLECTIN as her pregnancy progresses.
4. CONTRAINDICATIONS
DICLECTIN is contraindicated in women with any of the following conditions:
Known hypersensitivity to doxylamine succinate, other ethanolamine derivative antihistamines, pyridoxine hydrochloride or any inactive ingredient in the formulation.
Monoamine oxidase (MAO) inhibitors intensify and prolong the adverse central nervous system effects of DICLECTIN [see Drug Interactions (7.1) – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information].